TerraPower writes in LinkedIn about its cancer treatments.
- Advanced nuclear energy company TerraPower is also developing cancer medicine through its subsidiary TerraPower Isotopes (TPI).
- TPI is working with the Department of Energy to harvest Actinium-225 from Uranium-233 stockpiles which can then be turned into cancer-fighting drugs.
- Private sector innovation is driving clean energy and health progress.
“TerraPower Isotopes aims to bring a scalable solution to the precision medicine market. The proven production methods that TPI employs, along with the vital work of public and private partners, will establish a reliable supply of Actinium-225, and the delivery of this key isotopic starting material to drug developers. This enhanced Actinium-225 supply chain will enable the advancement of drug development trials and increase the research and deployment of advanced cancer treatment options.”
Read the full article here.
The views and opinions expressed are those of the author’s and do not necessarily reflect the official policy or position of C3.
